EMA/422871/2012

European Medicines Agency decision

P/0121/2012

of 3 July 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral for lumacaftor (EMEA-001173-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0121/2012

of 3 July 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral for lumacaftor (EMEA-001173-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Voisin Consulting SARL on 6 June 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 May 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for lumacaftor, film-coated tablet, age appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for lumacaftor, film-coated tablet, age appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Voisin Consulting SARL, 3, rue des Longs Prés, 92100 - Boulogne-Billancourt, France.

Done at London, 3 July 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/150719/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-001173-PIP01-11

Scope of the application

Active substance(s):

Lumacaftor

Condition(s):

Treatment of cystic fibrosis

Pharmaceutical form(s):

Film-coated tablet

Age appropriate oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Voisin Consulting SARL

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Voisin Consulting SARL submitted for agreement to the European Medicines Agency on 6 June 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 13 July 2011.

Supplementary information was provided by the applicant on 27 February 2012. The applicant proposed modifications to the paediatric investigation plan.

A meeting with the Paediatric Committee took place on 14 May 2012.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 16 May 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition: treatment of cystic fibrosis

2.1.1. Indication(s) targeted by the PIP

Treatment of cystic fibrosis in co-administration with ivacaftor

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age appropriate oral formulation

2.1.4. Studies

Area	Number of studies	Description
Quality	2	1. Development of a film-coated tablet. 2. Development of an age appropriate oral formulation for children below 6 years of age with testing of acceptability, palatability, and compatibility of the formulation with common food and drinks.
Non-clinical	7	3. 6-month oral (gavage) toxicity and toxicokinetics study with lumacaftor and VRT-0995096 in rats with a 1-month recovery (VX-809-TX-012). 4. 3-month oral (gavage) toxicity and toxicokinetics study with lumacaftor, ivacaftor, and VRT-0995096 in rats with a 1-month recovery (VX-809-TX-013). 5. 12 month oral (gavage) toxicity and toxicokinetics study with lumacaftor in Beagle dogs with a 1-month recovery (VX-809-TX-014). 6. Developmental and Perinatal/Postnatal Reproduction Toxicity Study in Rats, Including a Postnatal Behavioral/Functional Evaluation (VX-809-TX-017). 7. Fertility and early embryonic development study in rats with lumacaftor and VRT-0995096 (VX-809-TX-016). 8. Oral (gavage) dose range finding study in juvenile rats (VX-809-TX). 9. Oral (gavage) toxicity and toxicokinetics study in juvenile rats with 4-week recovery (VX-809-TX).

Area	Number of studies	Description
Clinical	6	10. Open-label, parallel-group, multi-centre trial to evaluate the PK of lumacaftor, ivacaftor and their respective major circulating metabolites in patients with Cystic Fibrosis (CF) and a F508del-CFTR mutation aged 6 to less than 18 years. (Study P1) 11. Randomised, double-blind, placebo-controlled trial to evaluate efficacy and safety in patients with CF and a F508del-CFTR mutation aged 6 to less than 12 years. (Study P2a) 12. Randomised, double-blind, placebo-controlled trial to evaluate efficacy and safety in patients with CF and a F508del-CFTR mutation aged 12 to less than 18 years (and adults). (Study P2b) 13. Rollover open-label long-term safety and efficacy study in patients with CF and a F508del-CFTR mutation aged 6 to less than 18 years (and adults) (Study P3) 14. Pharmacokinetic and Pharmacodynamic Study in patients with CF and a F508del-CFTR mutation aged 0 to less than 6 years (P4). 15. Relative bioavailability study to characterize the PK of the paediatric age appropriate formulation relative to the tablet formulation in healthy adults.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2017
Deferral for one or more studies contained in the paediatric investigation plan:	Yes